Submit site search
  • Optogenetic experiments with iLID system

    By on

    This protocol details experiments with the iLID optogenetic system as performed to acutely recruit Miro to mitochondria.

  • Endosomal escape of RNA therapeutics: How do we solve this rate-limiting problem?

    By on

    With over 15 FDA approved drugs on the market and numerous ongoing clinical trials, RNA therapeutics, such as small interfering RNAs (siRNAs) and antisense oligonucleotides (ASOs), have shown great potential to treat human disease. Their mechanism of action is based entirely on the sequence of validated disease-causing genes without the prerequisite knowledge of protein structure, activity or cellular location. In contrast to small molecule therapeutics that passively diffuse across the cell membrane's lipid bilayer, RNA therapeutics are too large, too charged, and/or too hydrophilic to passively diffuse across the cellular membrane and instead are taken up into cells by endocytosis. However, endosomes are also composed of a lipid bilayer barrier that results in endosomal capture and retention of 99% of RNA therapeutics with 1% or less entering the cytoplasm. Although this very low level of endosomal escape has proven sufficient for liver and some CNS disorders, it is insufficient for the vast majority of extra-hepatic diseases. Unfortunately, there are currently no acceptable solutions to the endosomal escape problem. Consequently, before RNA therapeutics can be used to treat widespread human disease, the rate-limiting delivery problem of endosomal escape must be solved in a nontoxic manner.

  • 3H-α-synuclein

    By on

    Mammalian expression of 3H-alpha-synuclein

  • Quantifying the LAMP1 positive puncta

    By on

    This protocol describes quantifying the LAMP1 positive puncta.

  • Neurite_FISH_Quant–Python code for quantification of FISH puncta in neurites

    By on

    This repository contains Jupyter Notebooks with Python 3 code for quantification of FISH puncta within neuronal dendrites or axons. However, prior identification of FISH puncta in the images (and optional neurite segmentation) is required. We use ImageJ plugins for this purpose, as specified below. The workflow assumes Z-stack, multi-channel fluorescence images, with one channel used for identification of neurites and other channels for FISH.

  • Peripheral neuronal activation shapes the microbiome and alters gut physiology

    By on

    The authors specifically activate ChAT- or TH-expressing gut-associated neurons in mice and perform multi-omics, finding that subsets of peripherally-activated neurons differentially regulate the gut microbiome and host GI physiology.

  • Plasmid: V5-KANSL1 pLVX-EF1α-IRES-Puro

    By on

    Plasmid: Human KANSL1 cDNA with N-terminal V5 tag cloned into the pLVX-EF1α-IRES-Puro plasmid (EcoRI and SpeI restriction sites) from Clontech, Takara Bio.

  • Nuclear Isolation of Post-Mortem Brain Tissue for snRNAseq

    By on

    This protocol details how to isolate nuclei from frozen brain tissue for single nuclear RNA sequencing using 10x Genomics GEM isolation using the Chromium accessory and Single Cell 3ʹ Reagent Kits.

  • pCAG-OSF-ATG13 (2-197)-K15D

    By on

    Plasmid for expression of human ATG13 HORMA K15D mutant in mammalian cells.

  • Immunohistochemistry for Carbon Fiber Thread Electrodes

    By on

    Methods for immunofluorescent staining of brain tissue with indwelling electrodes.

  • Determination of NM Concentration

    By on

    This is the protocol for determining neuromelanin concentration and data.

  • cDNA clones for expression of LysoTag (TMEM192) in mammalian cells

    By on

    Plasmids for expression of TMEM192 (LysoTag) in human and mouse cells.

  • pCAG- WIPI2dC93E-cs- TEV-STREP

    By on

    Plasmid: Mammalian expression of human WIPI2d C93E with C-terminal Strep.

  • Stereotaxic injection of viral vectors

    By on

    Stereotaxic injection of viral vectors

  • A step forward for LRRK2 inhibitors in Parkinson’s disease

    By on

    In common with the majority of neurodegenerative diseases, there is an urgent and pressing need for novel disease modifying therapies for Parkinson’s disease (PD). Reporting the results of the first human trial for kinase inhibitors of Leucine Rich Repeat Kinase 2 (LRRK2), Jennings and co-workers presented an important advance along the drug development pathway for a target that has long been a priority for the Parkinson’s research community. The focus discusses several topics including: functional characterisation of LRRK2 and the impact of mutations and a key role for altered kinase function in disease; the human genetics of the LRRK2 locus; the outcome of a first-in-human clinical trial for LRRK2 kinase inhibitors by Denali therapeutics, LRRK2 kinase inhibition as a therapeutic strategy in humans; the strategy of using antisense oligonucleotide knockdown approach and the challenges faced by clinical trials – measuring outcomes in chronic, slowly progressing disorders with variable rates of progression.

  • Surface Density Calculation

    By on

    This protocol details Surface Density Calculation.

  • Immunofluorescent staining for neuronal marker MAP2

    By on

    This is the protocol for immunofluorescent staining for neuronal marker MAP2.

  • Expansion Microscopy

    By on

    Expansion microscopy is a technique to visualize biological structures with higher spatial resolution than traditional microscopy methods.

  • 3D-correlative FIB-milling and Cryo-ET of Autophagic structures in Yeast Cells

    By on

    This protocol describes how to plunge-freeze yeast on EM grids and how to target autophagic structures by combining cryo confocal fluorescence data to FIB-milling and tomogram acquisition.

  • His-ATG3-H266A

    By on

    Plasmid for ATG3 mutant H266A overexpression in E.Coli.

Load More
Aligning Science Across Parkinson's
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.